Pharmaceutical agents for inhibiting the production of 20-HETE which participates in constriction or dilation of microvessels in major organs such as the kidneys and the cerebral blood vessels, or participates in causing cell proliferation are provided. The present invention relates to hydroxyamidine compounds represented by the formula:
wherein R 1 represents a group represented by the formula: R 2 -(CH 2 ) m - (wherein R 2 represents a C 3-8 cycloalkyl group, a C 2-6 alkoxycarbonyl group, a C 2-10 alkenyl group, a C 2-6 alkynyl group, a substituted or non-substituted aryl group, or the like, and m is an integer of 1 to 8), a group represented by the formula: R 3 -A- (wherein R 3 represents a hydrogen atom, a C 1-6 alkoxy group, a C 3-8 cycloalkoxy group, or the like, and A represents a straight-chain C 2-10 alkylene group which may be substituted with a C 1-6 alkyl group or a trifluoromethyl group), or a C 3-8 cycloalkyl group, and X represents an oxygen atom or a sulfur atom,
or pharmaceutically acceptable salts thereof, and relates to medicines including the same as active ingredients.